Quick Facts: Vitamin K3

• Therapeutic Area: Addresses certain types of vitamin K deficiency, which may affect normal blood clotting processes.
• Primary Use: Used to manage hypoprothrombinemia (a condition involving reduced blood clotting factors) that may occur due to certain medical conditions.

---

Vitamin K3, also known as menadione, is a synthetic precursor to active forms of vitamin K. While Vitamin K1 (phytonadione) and K2 (menaquinone) are the forms primarily used and recommended for human nutrition and therapy, Vitamin K3 has an established history of use in some limited therapeutic contexts related to vitamin K metabolism. Specifically, it is utilized as an agent to address instances of vitamin K deficiency that may manifest as hypoprothrombinemia. Hypoprothrombinemia is a condition characterized by a reduced level of prothrombin and other vitamin K-dependent clotting factors, which supports the maintenance of normal blood coagulation.

Historically, menadione preparations have been studied and used to contribute to the body's pool of active vitamin K, particularly in scenarios where the body’s ability to use or convert other forms is affected. The objective is to facilitate the production of essential clotting factors in the liver. It is important to note that the use of menadione in human medicine has largely been superseded by the natural forms of vitamin K due to safety considerations, and its current approved use may be limited to specific, specialized indications, often at low concentrations. The application of menadione and its derivatives remains restricted to these specific therapeutic contexts.

Who Can and Cannot Use Vitamine K3 (Menadione)

The eligibility profile for Menadione (Vitamin K3) is strictly defined by regulatory documents, emphasizing clear prohibitions due to known risks associated with this synthetic derivative.

---

Absolute Contraindications

Official labeling mandates that Menadione must not be used in the following populations:

• Neonates and Premature Infants: Strictly contraindicated due to the high risk of severe complications, including haemolytic anemia and kernicterus.
• G6PD Deficiency: Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are contraindicated due to the potential for inducing haemolysis.
• Severe Hepatic Impairment: Patients with pre-existing severe liver disease or jaundice must not use this medicine.
• Hypersensitivity: Individuals with a known allergic reaction or hypersensitivity to Menadione or its related derivatives.

---

Restricted and Conditional Use

• Age-Related Eligibility: Use is generally restricted and not recommended in children and adolescents.
• Reproductive Status: The medicine is generally not recommended for use in pregnant or breastfeeding women.
• Approved Population: Use is primarily restricted to adults for licensed indications, provided no contraindications are present.

Vitamin K3, also known as menadione, is a synthetic form of Vitamin K with important clinical considerations regarding interactions with other drugs and supplements. It is primarily involved in the synthesis of blood clotting factors, and its use must be carefully managed, especially in patients taking anticoagulants.

Major Interactions

Interacting Product	Effect of Interaction	Clinical Significance
Oral Anticoagulants (e.g., Warfarin)	Vitamin K3 directly opposes the effect of Vitamin K antagonists, reducing their anticoagulant activity and increasing the risk of blood clot formation.	High (Requires dose adjustment and close monitoring of coagulation tests.)

Other Significant Interactions

• High-Dose Vitamin E (Alpha-Tocopherol): Large supplemental doses of Vitamin E may antagonize the action of Vitamin K by interfering with its metabolism, potentially leading to an increased risk of bleeding. This effect is more pronounced in individuals with poor Vitamin K status.
• Thrombolytic Agents: Vitamin K3 may decrease the therapeutic efficacy of medications used to dissolve blood clots (e.g., Alteplase) due to its role in promoting coagulation.

Patients should always inform their healthcare provider about all medications, over-the-counter products, and dietary supplements they are taking to identify and manage potential interactions with Vitamin K3.

Menadione (Vitamin K3) functions as a synthetic provitamin, requiring metabolic conversion, primarily in the liver, to become the active cofactor, Menaquinone-4 ( MK-4). This mechanism directly influences the cascade leading to blood coagulation.

Provision of the Essential Enzyme Cofactor

The MK-4 molecule serves as the indispensable cofactor for the enzyme gamma-Glutamyl Carboxylase ( GGCX), which is tasked with activating precursor clotting proteins. By successfully supplying this factor and supporting the Vitamin K Cycle (including the VKORC1 recycling enzyme), the drug contributes to maintaining the activity of the coagulation pathway.

Enabling Clotting Factor Function Through Ca^2+ Binding

The core molecular action is the enablement of a post-translational modification. The GGCX enzyme performs gamma-carboxylation on clotting factor precursors ( II, VII, IX, X). This specific chemical modification creates Gla residues, granting the proteins the functional ability to bind calcium ions ( Ca^2+). This Ca^2+-dependent binding capacity is the absolute prerequisite for the factors to anchor to cell surfaces at a wound site, thereby initiating the Coagulation Cascade and facilitating the assembly of coagulation complexes required for hemostasis.

Menadione, often used via its water-soluble derivatives like Menadiol Diphosphate, operates under clinical guidelines that define the manner of its use in clinical practice. This structure ensures adherence to standard administration principles.

Administration Scope

Entity	Instruction
Route of Administration	The administration route is Oral, utilizing a tablet formulation, which is the primary method defined for this compound.
Dosing Schedule	The standard adult therapeutic dose is typically 10 mg to 40 mg daily. For children, the suggested daily dose is a range of 5 mg to 20 mg of the active ingredient.
Frequency and Timing	The medication is scheduled for Once Daily administration. If a dose is missed, the patient is instructed to skip it and resume the normal schedule if the next dose is due shortly; double doses are strictly prohibited to compensate for the missed administration.
Age-Group Rules	Dose recommendations for older adults do not differ from those set for the general adult population.

Procedural Structure and Use Context

The overall procedural structure dictates that the therapeutic use is designated as a short-term course aimed at specific, time-limited interventions. For correct administration, standard procedural instructions specify that where tablets are scored, they may be divided into equal doses to precisely match the prescribed milligram amount. Furthermore, the product must be protected from light and stored in its original container to preserve the chemical potency of the active substance prior to intake.

Vitamine K3 (Menadione): Recent Clinical Evidence

Vitamin K3, also known as menadione, is a synthetic form of vitamin K that does not occur naturally in the diet. Unlike the naturally occurring forms, K1 (phylloquinone) and K2 (menaquinone), menadione is not generally available or used as a nutritional supplement or prescription drug for humans in many economically developed countries.

Safety and Regulatory Status

Historical research in the 1980s and 1990s linked menadione to potential toxic effects in humans, specifically mentioning liver damage and hemolytic anemia (the destruction of red blood cells). Due to these safety concerns, menadione was restricted and is now primarily used in animal feeds as a source of vitamin K activity. In certain regions, it may still be available at pharmaceutical strength for specific clinical uses, such as the treatment of hypoprothrombinemia (a bleeding disorder).

Investigational Research

Despite its safety profile concerns in humans, menadione has been the subject of investigational, non-clinical research due to certain biological activities:

• Anticancer Studies: Laboratory (in vitro) studies have explored menadione’s ability to induce programmed cell death (apoptosis) in various human cancer cell lines, including breast, prostate, and colorectal cells.
• Adjuvant Activity: Research has investigated menadione as a compound that may enhance the activity of certain antibiotics against drug-resistant bacteria in laboratory settings.
• Topical Application: Small-scale clinical studies have explored menadione in topical formulations to evaluate its safety and potential to mitigate skin side effects associated with specific cancer treatments (e.g., EGFR inhibitors). These studies focus on local, rather than systemic, effects.

It is important to note that these investigational findings are preliminary and do not constitute clinical recommendations for use in humans. Further research is necessary to evaluate potential benefits against documented safety risks.

Common questions about Vitamine K3 (FAQ)

Q: What is the main difference between Vitamine K3 and other forms of Vitamin K like K1 and K2?

A: Vitamine K3 (menadione) is classified as a synthetic provitamin, meaning it is manufactured chemically and requires conversion by the body, mainly into Menaquinone-4 (MK-4). This differs from the naturally occurring Vitamine K1 (phylloquinone) and Vitamine K2 (menaquinone).

Unlike the natural forms, the absence of a side chain is noted in official documents as being associated with lower chemical stability and potential toxicity, which informed restrictions on its use.

Q: Is Vitamine K3 a prescription drug or can it be purchased over-the-counter?

A: Vitamine K3 is listed in regulatory systems as a pharmaceutical substance, such as Menadione sodium bisulfite, which is suitable for injectable and oral drug preparations. Its use is generally restricted to licensed indications and is subject to prescription and medical oversight.

Q: How quickly can a person expect to see any effects after starting Vitamine K3?

A: Official labeling often does not provide a specific timeline for the onset of effect for oral Vitamine K3 formulations. However, for related Vitamin K compounds administered by injection, effects on clotting factors have been observed within a few hours, and the maximum effect is often cited to occur within 6 to 12 hours.

Q: Is a metallic taste a known side effect of Vitamine K3?

A: Official adverse reaction lists for Vitamin K preparations have occasionally documented peculiar or transient changes in taste, particularly following non-oral administration. This suggests that taste-related side effects are a documented, though less common, effect.

Q: Can Vitamine K3 cause digestive issues like stomach upset or nausea?

A: Regulatory safety data sheets for the active ingredient or related preparations mention that ingestion can cause gastrointestinal irritation. Effects such as nausea, vomiting, and diarrhea have been noted, suggesting that digestive issues are a potential effect noted in safety information.

Q: Are there any long-term side effects associated with taking Vitamine K3?

A: Official safety documents focus mainly on acute risks, such as serious toxicity like hemolytic anemia. Regulatory information on specific long-term, non-acute side effects is generally limited, as its therapeutic use is designated as a short-term course.

Q: Are there different brand names for the same Vitamine K3 product?

A: Regulatory systems and pharmaceutical reference sites list several brand names (e.g., HYKINONE, K-THROMBIN, KLOTOGEN) historically associated with the pharmaceutical preparations of the Menadione sodium bisulfite complex. These names may represent various forms, formulations, or markets for the same core compound.

Q: What is the general classification of Vitamine K3 (e.g., vitamin, supplement, drug)?

A: Menadione (Vitamine K3) is formally classified as a synthetic analog and provitamin K, belonging to the Vitamin K derivative pharmacological class. It is utilized in pharmaceutical preparations for its clinical role in supporting blood coagulation.

Q: Are there any warnings about driving or operating machinery while on Vitamine K3?

A: Official adverse reaction lists for related Vitamin K products have included reports of effects such as dizziness and weakness. Regulatory information about these adverse neurological effects can be clinically relevant to activities like driving or operating machinery.

Q: How is the effectiveness of Vitamine K3 measured in studies?

A: The effectiveness is assessed by analyzing laboratory coagulation tests, such as the Prothrombin Time (PT) and the International Normalized Ratio (INR). These tests measure the functional activity of the blood clotting factors that the drug helps activate.

Q: What are the official sources for safety information on Vitamine K3?

A: Primary authoritative sources for safety information include official regulatory labeling from government agencies. Examples include the U.S. FDA's DailyMed, the UK's MHRA (SmPC), and various official substance and safety data sheets from bodies like the WHO, which compile technical and regulatory data.

Q: If I have a food allergy, is there a risk with Vitamine K3?

A: Official labeling explicitly advises against using Menadione if a person has a known hypersensitivity or allergic reaction to the compound or its derivatives. The product information does not typically list warnings regarding general food allergies.

Q: What is the significance of Vitamine K3 being synthetic?

A: Its synthetic nature is significant because it means the compound does not occur naturally in the diet and must be converted to become active. The absence of a long side chain is noted in official documents as being associated with lower chemical stability and a potential for toxicity, which informed restrictions on its use in humans.

Q: Is Vitamine K3 used for treating newborn bleeding disorders?

A: No. Official regulatory documents strictly contraindicate the use of Menadione (Vitamine K3) in neonates and premature infants. This restriction is mandated due to the serious, documented risk of toxicity, including a condition called kernicterus.

Q: Can Vitamine K3 be used to prevent a vitamin K deficiency?

A: Official procedural documentation indicates that the therapeutic use of the drug is designated as a short-term course aimed at treating specific coagulation issues, such as hypoprothrombinemia. Its primary role is treatment-based rather than for the routine prevention of a vitamin K deficiency.

Q: What is the difference in how Vitamine K3 is metabolized compared to K1?

A: Vitamine K3 is a provitamin that requires a specific metabolic conversion step (alkylation) to be chemically activated into Menaquinone-4 (MK-4). In contrast, Vitamine K1 (phylloquinone) is absorbed and can be utilized more directly by the body. Research also suggests K1 may have a different profile for retention in tissues compared to the Menadione forms.

Q: Is it true that Vitamine K3 is banned in some countries?

A: Official regulatory history indicates that the use of Menadione (Vitamine K3) has been heavily restricted or limited in certain jurisdictions. Due to historical safety concerns related to toxicity, its primary use in some regions is now restricted to animal feeds as a source of vitamin K activity.

Q: What is the recommended duration of treatment for Vitamine K3?

A: Official procedural documentation indicates that the therapeutic use of the drug is designated as a short-term course aimed at specific, time-limited interventions. A precise number of days or weeks for the course is not uniformly provided in the core label text.

Q: How does Vitamine K3 affect the synthesis of clotting factors?

A: Vitamine K3 is converted into an active cofactor that enables a key enzyme (gamma-Glutamyl Carboxylase) to activate precursor clotting proteins. This activation specifically targets factors II, VII, IX, and X and grants them the ability to bind calcium ions, which is required for the blood clotting process (hemostasis).

Storage and Disposal of Menadione (Vitamin K3)

Official labeling requires menadione preparations to be stored at controlled room temperature, typically 20 C to 25 C. To maintain stability, the product must be protected from light and kept in its original container.

Requirements Summary

Area	Mandate
Temperature	Controlled room temperature (20 C–25 C with excursions)
Protection	Protect from light; store in original container
Safety	Keep out of reach of children
Disposal	Dispose of unused product or waste material in accordance with local regulations

All expired or unused product must be discarded following local regulatory requirements for pharmaceutical waste.